Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: A nested case-control study
Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: A nested case-control study
复制标题
妊娠期糖尿病孕妇血浆白脂素持续升高：一项巢式病例对照研究
DOI：
10.1016/j.placenta.2020.02.004
复制
发表时间：
2020-04-01
期刊：
影响因子：
3.8
通讯作者：
Liu, Bin
中科院分区：
文献类型：
--
作者：
Zhong, Lieqiang;Long, Yuhang;Liu, Bin
简介：目的：探讨妊娠期糖尿病（GDM）孕妇血浆和胎盘中胰岛素抵抗相关因子白色脂肪肽（asprosin）的表达情况。本研究收集了40例GDM孕妇和40例糖耐量正常的对照组。在妊娠18-20周和24-28周以及分娩前通过ELISA检测母体血浆以及脐带血浆中的白色脂肪肽水平。比较GDM组和NGT组的白色脂肪肽浓度，并分析白色脂肪肽浓度与其他参数的关系。结果：经母儿临床特征和血脂谱调整后，妊娠期糖尿病孕妇及其后代血浆中白色脂肪素水平升高。Asprosin在GDM和NGT孕妇胎盘中均有表达。讨论：Asprosin蛋白在人胎盘中有表达，在GDM孕妇及其后代的血浆中表达升高。由于胰岛素抵抗相关因素在妊娠20周前增加，白色脂肪肽可能作为GDM的潜在早期生物标志物发挥作用。
Introduction: To investigate the expression of asprosin, a novel insulin resistance-related factor, in plasma and placenta of pregnant women with and without gestational diabetes mellitus (GDM).Methods: This is a nested case-control study within the prospective study named Early Diagnosis of Gestational Diabetes Mellitus (EDoGDM). Forty pregnant women with GDM and forty control cases with normal glucose tolerance (NGT) were recruited in the present study. Asprosin levels were tested by ELISA in maternal plasma at 18-20 and 24-28 gestational weeks and before delivery, as well as in umbilical plasma. Asprosin concentrations were compared between GDM and NGT groups, and the relationship between asprosin and other parameters were analyzed. Expression of asprosin in placenta was examined by Western blot and immunohistochemistry.Results: Asprosin was elevated in plasma of GDM pregnant women and their offspring, after adjusted by maternal and neonatal clinical characteristics and lipid profiles. Asprosin was expressed in placenta from both GDM and NGT pregnant women.Discussion: Protein asprosin is expressed in human placenta and is elevated in the plasma of pregnant women complicated with GDM and their offspring. As an insulin resistance-related factor increased before 20 gestational weeks, asprosin may play a role as a potential early biomarker of GDM.